Sodium hyaluronate has been discovered for nearly 80 years. As early as 1934, Meyer and Palmer hyaloid body isolated a polymeric polysaccharide containing uronic acid and aminohexose, and named it "hyaluronic acid". The word is formed by combining "hyaloid"(transparent, glassy) with "uronic acid", which is translated into "hyaluronic acid" in biochemical terms, and" hyaluronic acid" in Chinese pharmacopoeia and national pharmaceutical standards. In a physiologically neutral environment, hyaluronic acid is a polyanion. In 1985, Balazs et al. suggested the use of the word hyaluronan to name the substance uniformly, on the grounds that the substance is essentially a carbohydrate and should follow the naming rules of its glycosaminoglycan, that is, the suffix an. Hyaluronan "has been widely used to contain hyaluronate and its salts in any state, often translated as" hyaluronate "or HA. Currently, the approved HA product is commonly referred to as "sodium hyaluronate injection" and the approved HA product is called "sodium hyaluronate gel for medical use". In the early 1970 s, the United States first developed the first of the material can be used in human clinical products, in view of the product is used in ophthalmic microsurgery, cataract surgery, its main function is to clinicians as pad, ophthalmic microsurgery of surgery with temporary support operation space, convenient operation, so to instrument examination and approval and sale, then this product in orthopedics, surgery thereafter, to equipment sale approval document. Therefore, the FDA of the United States recognized the substance as a medical device.